Preview

Современная ревматология

Расширенный поиск

Значение качества жизни, связанного со здоровьем, у больных системной красной волчанкой и современные инструменты его оценки

https://doi.org/10.14412/1996-7012-2017-4-62-72

Полный текст:

Аннотация

Представлен обзор исследований, посвященных оценке качества жизни, связанного со здоровьем (КЖСЗ), у больных системной красной волчанкой (СКВ). Описаны концепция КЖСЗ, а также предпосылки ее создания. Рассмотрена классификация опросников, применяемых у пациентов СКВ, в зависимости от задач, поставленных в исследовании. У больных СКВ на основании многих исследований выведена основная ключевая триада проблем (усталость, боль и депрессия), вызывающая ухудшение КЖСЗ. Приведена краткая сравнительная характеристика восьми специфических опросников для оценки КЖСЗ у больных СКВ: SLE Symptom checklist (SSC), SLEQol, LupusQol, L-Qol, LupusPRO и Lupus Impact Traker (LIT), LUP-QoL, SMILEY. Отдельное внимание уделено оценке КЖСЗ у больных, получающих разные виды лечения: глюкокортикоиды, цитостатическую, анти-В-клеточную терапию.

 

Об авторах

Л. Д. Воробьева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия


Е. А. Асеева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия


Литература

1. Насонова ВА. Системная красная волчанка. Москва: Медицина; 1972. 230 c. [Nasonova VA. Sistemnaya krasnaya volchanka [Systemic lupus erythematosus]. Moscow: Meditsina; 1972. 230 p.]

2. Соловьев СК, Асеева ЕА, Попкова ТВ и др. Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Pекомендации международной рабочей группы и комментарии российских экспертов. Научно-практическая ревматология. 2015;53(1):9–16. [Solov'ev SK, Aseeva EA, Popkova TV, et al. Strategiya lecheniya sistemnoi krasnoi volchanki «do dostizheniya tseli» (Treat-to-Target SLE). Treat-to-target SLE recommendations from the international task force and russian experts’ commentaries. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(1):9–16. doi:10.14412/1995-4484-2015-9-16. (In Russ.)].

3. Колпакова ЕВ. Качество жизни и артериальная гипертония: роль оценки качества жизни в клинических исследованиях и практической деятельности врача. Терапевтический архив. 2000;72(4):71-4. [Kolpakova EV. Quality of life and hypertension: the role of quality of life assessment in clinical research and practical activities of the doctor. Terapevticheskii arkhiv. 2000;72(4): 71-4. (In Russ.)].

4. Kaplan R, Bush J. A related quality of life for evaluation research and policy analyses. Health Psychol. 1982;1(1): 61–80. doi: 10.1037/0278-6133.1.1.61

5. Новик АА, Ионова ТИ, Кайнд П. Концепция исследования качества жизни в медицине. Санкт-Петербург: Элби; 1999. 140 с. [Novik AA, Ionova TI, Kaind P. Kontseptsiya issledovaniya kachestva zhizni v meditsine [The concept of quality of life studies in medicine]. Saint-Petersburg: Elbi; 1999.140 p.]

6. Новик АА, Матвеев СА, Ионова ТИ. Оценка качества жизни больного в медицине. Клиническая медицина. 2000; (2):10-3. [Novik AA, Matveev SA, Ionova TI. Assessment of the quality of life of the patient in medicine. Klinicheskaya meditsina. 2000; (2): 10-3. (In Russ.)].

7. Wood-Dauphinee S. Assessing quality of life in clinical research: from where have we come and where are we going? Clin Epidemiol. 1999 Apr;52(4):355-63.

8. Shumaker S, Naughton M. The International Assessment of Health Related Quality of Life: A theoretical perspective. In: The International Assessment of Health Related Quality of Life: Theory, Translation, Measurement and Analysis. Oxford; 1995. P. 34-42.

9. Pais-Ribeiro JL. Quality of life is a primary endpoint in clinical settings. Clin Nutr. 2004 Feb;23(1):121-30.

10. Michalos AC. Social Indicators Research and Health-Related Quality of Life Research. Social Indicators Research. 2004;65(1):27-72. doi: https://doi.org/10.1023/A:1025592 219390

11. Vankova D. Acro conceptual and methodological approaches to quality of life – a public health perspective. Scripta Scientifica Salutis Publicae. 2015;1(2):7-13. doi: 10.14748/ sssp.v1i2.1380.

12. Holmes S, Dickerson J. The quality of life design and evaluation of a self-assesment instrument for use with cancer patients. Int J Nurs Stud. 1987;24(1):15-24.

13. Holloway L, Humphrey L, Heron L, et al. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance. Health Qual Life Outcomes. 2014 Jul 22;12:116. doi: 10.1186/ s12955-014-0116-1.

14. Danoff-Burg S, Friedberg F. Unmet needs of patient with systemic lupus erythematosus. Behav Med. 2009 Spring;35(1):5-13. doi: 10.3200/BMED.35.1.5-13.

15. Moses N, Wiggers J, Nicholas C, Cockburn J. Prevalence and correlates of perceived unmet needs of people with Systemic Lupus Erythematosus. Patient Educ Couns. 2005 Apr;57(1):30-8.

16. Zonana-Nacach A, Roseman J, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. Lupus. 2000;9(2):101-9. doi: 10.1191/096120300678828046.

17. Harboe E, Greve O, Beyer M, et al. Fatigue is associated with cerebral white matter hyperintensities in patients with systemic lupus erythematosus. J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):199-201. Epub 2007 Sep 14.

18. Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of Fatigue in Systemic Lupus Erythematosus: A Systematic Review. Arthritis Rheum. 2007 Dec 15;57(8):1348-57.

19. Gallop K, Nixon A, Swinburn P, et al. Development of a conceptual model of health-related quality of life for systemic lupus erythematosus (SLE) from the patients’ perspective. Lupus. 2012 Aug;21(9):934-43. doi: 10.1177/0961203312441980. Epub 2012 Mar 20.

20. Mattsson M, Mö ller B, Stamm T, et al. Uncertainty and Opportunities in Patients with Established Systemic Lupus Erythematosus: A Qualitative Study. Musculoskeletal Care. 2012 Mar;10(1):1-12. doi: 10.1002/msc.220. Epub 2011 Oct 18.

21. McElhone K, Abbott J, Gray J, et al. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus. 2010 Dec;19(14):1640-7. doi: 10.1177/0961203310378668. Epub 2010 Aug 13.

22. Seawell A, Danoff-Burg S. Body image and sexuality in women with and without Systemic Lupus Erythematosus. Sex Roles. 2005;53(11–12):865–83. doi: 10.1007/ s11199-005-8298-y.

23. Lederman L, Lindner H, Greenwood K, Philip E. Depression and pain in night time and daytime functioning of individuals with Lupus. Psychol Health. 2008;23(5):537-50.doi: 10.1080/08870440701724849.

24. Kulczycka L, Sysa-Jedrzejowska A, Robak E. Life satisfaction together with positive and negative aspects in Polish patients with Systemic Lupus Erythematosus. J Eur Acad Dermatol Venereol. 2009 Mar;23(3): 251-5. doi: 10.1111/j.1468-3083.2008. 03044.x. Epub 2008 Dec 18.

25. Doward L, McKenna S, Whalley D, et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009 Feb;68(2):196-200. doi: 10.1136/ard.2007. 086009. Epub 2008 Apr 2.

26. McЕlhone K, Abbott J, Shelmardine J, et al. Development and validation of a disease-specific health-related quality of life measure, the lupusQoL, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007 Aug 15;57(6):972-9.

27. Mendelson C. Managing a medically and socially complex life: Women living with Lupus. Qual Health Res. 2006 Sep;16(7):982-97.

28. Grootscholten C, Ligtenberg G, Derksen R, et al. Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual Life Res. 2003 Sep;12(6):635-44.

29. Leong K, Kong K, Thong B, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford). 2005 Oct;44(10): 1267-76. Epub 2005 Mar 29.

30. Yazdany J, Yelin E. Health-related quality of life and employment among persons with systemic lupus erythematosus. Rheum Dis Clin North Am. 2010 Feb;36(1):15-32, vii. doi: 10.1016/j.rdc.2009.12.006.

31. Yu E, Shikiar R, Howard K, et al. Validation of LUP-QOL: a lupus-specific measure of health-related quality of life (HRQL). Ann Rheum Dis. 2006;65(2):601.

32. Moorthy L, Peterson M, Baratelli M, et al. Multicenter validation of a new quality of life measure in pediatric lupus. The development and validation of SMILEY as a brief, easily understood, valid, and reliable pediatric, SLE-specific QoL scale are described. Arthritis Rheum. 2007 Oct 15;57(7):1165-73.

33. Jolly M, Yazdany J, Yelin E, et al. Disease-Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus: Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort. Arthritis Rheum. 2008 Jan 15;59(1):136-43. doi: 10.1002/art.23238.

34. Jolly M. Disease-Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus. Semin Arthritis Rheum. 2012 Aug;42(1):56-65. doi: 10.1016/j.semarthrit.2011.12.005. Epub 2012 Apr 4.

35. Jolly M, Gandhi N, Nevares A, et al. Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015; 67(Suppl 10):787.

36. Jolly M, Garris C, Mikolaitis R, et al. Development and validation of the Lupus Impact Tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014 Oct;66(10): 1542-50. doi: 10.1002/acr.22349.

37. Jolly M, Kosinski M, Garris C, Oglesby A. Prospective Validation of the Lupus Impact Tracker: A Patient-Completed Tool for Clinical Practice to Evaluate the Impact of Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016 Jun;68(6):1422-31. doi: 10.1002/art.39601.

38. Jolly M, Pickard A, Wilke R, et al. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis. 2010 Jan;69(1):29-33.

39. doi: 10.1136/ard.2008.094763.

40. Devilliers H, Amoura Z, Besancenot J, et al. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2012 Oct; 51(10):1906-15. Epub 2012 Jul 22.

41. Wang S, Wu B, Leng L, et al. Validity of LupusQoL-China for the Assessment of Health Related Quality of Life in Chinese Patients with Systemic Lupus Erythematosus. PLoS One. 2013 May 23;8(5):e63795. doi: 10.1371/journal.pone.0063795. Print 2013.

42. Conti F, Perricone C, Reboldi G, et al. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus. 2014 Jul;23(8):743-51. doi: 10.1177/0961203314524466. Epub 2014 Feb 25.

43. Pamuk O, Onat A, Donmez S, et al. Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients. Lupus. 2015 Jul;24(8):816-21. doi: 10.1177/0961203314565412. Epub 2014 Dec 26.

44. Machado Escobar M, Yacuzzi M, Martinez R, et al. Validation of an Argentine version of Lupus Quality of Life questionnaire. Lupus. 2016 Dec;25(14):1615-1622. Epub 2016 Jul 20.

45. Hosseini N, Bonakdar Z, Gholamrezaei A, Mirbagher L. Linguistic Validation of the LupusQoL for the Assessment of Quality of Life in Iranian Patients with Systemic Lupus Erythematosus. Int J Rheumatol. 2014;2014: 151530. doi: 10.1155/2014/151530. Epub 2014 Sep 9.

46. McElhone K, Abbott J, Sutton C. Sensitivity to Change (Responsiveness) and Minimal Important Differences of the LupusQoL in patients with Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2016 Oct;68(10):1505-13. doi: 10.1002/acr. 22850. Epub 2016 Sep 2.

47. Hanly J. Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: results of a cross-sectional study. Lupus. 1997;6(3):243-7.

48. Gladman D, Urowitz M, Ong A, et al. Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol. 1996 May-Jun;14(3):305-8.

49. Stoll T, Gordon C, Burckhardt C, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol. 1997 Aug; 24(8):1608-14.

50. Benjamin C, Perneger T, Trendelenburg M, et al. Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS) for the Swiss Systemic Lupus Erythematosus Cohort Study Group. BMC Immunol. 2017 Mar 28; 18(1):17. doi: 10.1186/s12865-017-0200-5.

51. Plantinga L. Association of age with health-related quality of life in a cohort of patients with systemic lupus erythematosus: the Georgians Organized Against Lupus study. Lupus Sci Med. 2016 Jul 19;3(1): e000161. doi: 10.1136/lupus-2016-000161. eCollection 2016.

52. Vu T, Escalante A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. J Rheumatol. 1999 Dec;26(12): 2595-601.

53. Stoll T, Stucki G, Malik J, et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis. 1996 Oct;55(10): 756-60.

54. Thumboo J, Fong K, Ng TP, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol. 1999 Jan;26(1):97-102.

55. Marx C, Mö rgeli HP, Bü chi S, Stoll T. Are there associations of health status, disease activity and damage in SLE patients? Results of a study of a cohort of a Swiss specialized outpatient clinic. Praxis (Bern 1994). 2007 May 30;96(22):895-9.

56. Sutcliffe N, Clarke A, Levington C, et al. Associates of health status in patients with systemic lupus erythematosus. J Rheumatol. 1999 Nov;26(11):2352-6.

57. Dobkin PL, DaCosta D, Dritsa M, et al. Quality of life in systemic lupus erythematosus patients during more or less active disease states: differential contributors to mental and physical health. Arthritis Care Res. 1999 Dec; 12(6):401-10.

58. Zhu T, Tam L, Lee V, et al. Relationship Between Flare and Health-related Quality of Life in Patients with Systemic Lupus Erythematosus. J Rheumatol. 2010 Mar;37(3): 568-73. doi: 10.3899/jrheum.090876. Epub 2010 Jan 28.

59. Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford). 2004 Dec;43(12):1580-6. Epub 2004 Sep 14.

60. Barnado A, Wheless L, Meyer A, et al. Quality of life in patients with systemic lupus erythematosus (SLE) compared with related controls within a unique African American population. Lupus. 2012 Apr;21(5):563-9. doi: 10.1177/0961203311426154. Epub 2011 Oct 26.

61. Strand V, Chu A. Generic versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus. J Rheumatol. 2011 Sep;38(9):1821-3. doi: 10.3899/jrheum.110766.

62. Barbosa C, Balp M, Kulich K, et al. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39-48. doi: 10.2147/PPA. S24752. Epub 2012 Jan 13.

63. Delestras S, Roustit M, Bedouch P, et al. Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases. PLoS One. 2013;8(2): e56247. doi: 10.1371/journal.pone.0056247.

64. Pino-Sedeno T, Ruiz-Irastorza , Cuellar-Pompa L, et al. Effectiveness of Nonpharmacologic Interventions for Decreasing Fatigue in Adults With Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res (Hoboken). 2016;68(1): 141-8. doi: 10.1002/acr.22675.

65. Robb-Nicholson L, Daltroy L, Eaton H, et al. Effects of aerobic conditioning in lupus fatigue: a pilot study. Br J Rheumatol. 1989 Dec;28(6):500-5.

66. Tench C, McCarthy J, McCurdie I, et al. Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology (Oxford). 2003;42 (9):1050-4. doi: 10.1093/rheumatology/keg289.

67. Navarrete-Navarrete N, Peralta-Ramirez M, Sabio J, et al. Quality-of-life predictor factors in patients with SLE and their modification after cognitive behavioural therapy. Lupus. 2010;19(14):1632–9. doi: 10.1177/0961203310378413.

68. Jolly M, Galicier L, Auma??tre O, et al. Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloro-quine levels. Lupus. 2016 Jun;25(7):735-40. doi: 10.1177/0961203315627200.

69. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore. 2007;36(2):115–22.

70. Daleboudt G, Berger S, Broadbent E, Kaptein A. Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. Psychol Health Med. 2011 Aug;16(4):393-404. doi: 10.1080/13548506.2011.554566.

71. Grootscholten C, Snoek F, Bijl M, et al. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a ran-domized controlled trial. J Rheumatol. 2007 Aug;34(8):1699-707. Epub 2007 Jul 15.

72. Medeiros M, Menezes A, Silveira V, et al. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med. 2008;19(2):122–8. doi: 10.1016/j.ejim.2007.06.012.

73. Griffiths B, Emery P, Ryan V, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford). 2010;49(4):723-32. doi: 10.1093/rheumatology/kep396.

74. Wilson E, Jayne D, Dellow D, Fordham R. The cost-effectiveness of mycophenolate mofetil as first line therapy in active lupus nephritis. Rheumatology (Oxford). 2007;46(7);1096–101. doi: 10.1093/rheumatology/kem054.

75. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phaseI/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007;17(3):191-7. Epub 2007 Jun 20. doi: 10.1007/s10165-007-0565-z.

76. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78. doi: 10.1002/art.24699.

77. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with SF systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12): 3918-30. doi: 10.1002/art.30613.

78. Vollenhoven R, Parodis I, Levitsky A. Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol. 2013 Jun;27(3): 341-9. doi: 10.1016/j.berh.2013.07.006.

79. ACCESS Trial Group. Treatment of lupus nephritis with abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 2014 Nov;66(11):3096-104. doi: 10.1002/art.38790.

80. Szepietowski J, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013 Oct; 65(10):2661-71. doi: 10.1002/art.38091.

81. Hanly J. Disease activity, cumulative damage and quality of life in systemic lupus erythematosus: results of a cross-sectional study. Lupus. 1997;6(3):243-7. doi: 10.1177/ 096120339700600305.

82. Thumboo J, Fong K, Ng T, et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus patients in Singapore. J Rheumatol. 1999 Jan;26(1):97-102.

83. Thumboo J, Feng PH, Boey ML, et al. Validation of the Chinese SF-36 for quality of life assessment in patients with systemic lupus erythematosus. Lupus. 2000;9(9):708-12.

84. Touma Z, Gladman D, Ibanez D, Urowitz M. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol. 2011 Sep;38(9):1898-905. doi: 10.3899/jrheum.110007. Epub 2011 Jul 1.

85. Jolly M, Kazmi N, Mikolaitis A, et al. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol. 2013 Apr;68(4):618-23. doi: 10.1016/j.jaad.2012.08.035. Epub 2012 Oct 26.

86. Demirkaya E, Bilginer Y, Aktay-Ayaz N, et al. Neuropsychiatric involvement in juvenile systemic lupus erythematosus. Turk J Pediatr. 2008 Mar-Apr;50(2):126-31.

87. Daleboudt G, Berger S, Broadbent E, Kaptein A. Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis. Psychol Health Med. 2011;16(4):393-404.

88. doi: 10.1080/13548506.2011.554566.

89. Garcia M, Callejas R, Peralta-Ramirez M, et al. Impaired sexual function in women with systemic lupus erythematosus: a cross-sectional study. Lupus. 2013 Sep;22(10):987-95. doi: 10.1177/0961203313500370.

90. Arends S, Berden J, Grootscholten C,

91. et al. Induction therapy with short-term high dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis. Dutch Working Party on SLE. Neth J Med. 2014 Nov;72(9):481-90.

92. Wang S, Hsieh E, Zhu L, Wu B, Lu L. Comparative Assessment of Different Health Utility Measures in Systemic Lupus Erythematosus. Sci Rep. 2015;5:13297. doi: 10.1038/srep13297.

93. McElhone K, Burnell J, Sutton C, et al. Is the Disease specific Lupusqol Sensitive To Changes of Disease Activity In Systemic LupusErythematosus Patients After Treatment of A Flare? Value Health. 2014;17(7):A538. doi: 10.1016/j.jval. 2014.08.1725.

94. Mirbagher L, Gholamrezaei A, Hosseini N, et al. Sleep quality in women with systemic lupus erythematosus: contributing factors and effects on health-related quality of life. Int J Rheum Dis. 2016 Mar;19(3):305-11. doi: 10.1111/1756-185X. 12418. Epub 2014 Jun 9.

95. Gordon C, Isenberg D, Lerstr?m K, et al. The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. Rheumatology (Oxford). 2013;52(12): 2292-301. doi: 10.1093/rheumatology/ket300.


Для цитирования:


Воробьева Л.Д., Асеева Е.А. Значение качества жизни, связанного со здоровьем, у больных системной красной волчанкой и современные инструменты его оценки. Современная ревматология. 2017;11(4):62-72. https://doi.org/10.14412/1996-7012-2017-4-62-72

For citation:


Vorobyeva L.D., Aseeva E.A. Importance of health-related quality of life and its current assessment tools in patients with systemic lupus erythematosus. Modern Rheumatology Journal. 2017;11(4):62-72. (In Russ.) https://doi.org/10.14412/1996-7012-2017-4-62-72

Просмотров: 233


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)